Li Q, Yin LK. Comprehensive analysis of disulfidptosis related genes and prognosis of gastric cancer. World J Clin Oncol 2023; 14(10): 373-399 [PMID: 37970110 DOI: 10.5306/wjco.v14.i10.373]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Oct 24, 2023; 14(10): 373-399 Published online Oct 24, 2023. doi: 10.5306/wjco.v14.i10.373
Comprehensive analysis of disulfidptosis related genes and prognosis of gastric cancer
Qian Li, Long-Kuan Yin
Qian Li, Department of Oncology, Fushun Hospital of Traditional Chinese Medicine, Zigong 643200, Sichuan Province, China
Long-Kuan Yin, Department of Gastrointestinal Surgery, Fushun People’s Hospital, Zigong 643200, Sichuan Province, China
Author contributions: Li Q contributed to this work; Yin LK and Li Q prepared for the figures and tables; and all authors have approved the final manuscript.
Institutional review board statement: The data supporting the results of this study are available from Gene Expression Omnibus database (GSE84433andGSE26253) and the expression data, clinical data, mutation data, and copy data related to gastric cancer from The Cancer Genome Atlas database.
Conflict-of-interest statement: The authors deny any conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Received: July 30, 2023 Peer-review started: July 30, 2023 First decision: August 24, 2023 Revised: September 7, 2023 Accepted: September 18, 2023 Article in press: September 18, 2023 Published online: October 24, 2023 Processing time: 85 Days and 17.5 Hours
ARTICLE HIGHLIGHTS
Research background
Gastric cancer (GC) is one of the most common malignant tumors, although its pathogenesis remains unclear.
Research motivation
For the first time, in the current study, we constructed a new GC prognostic model based on the sub-group analysis of disulfidptosis-related genes (DRGs) and explored treatment targets and sensitive drugs.
Research objectives
The aims of this study were to explore a new GC prognostic model based on the sub-group analysis of DRGs and explore treatment targets and sensitive drugs.
Research methods
In this study, a bioinformatics strategy was used to extract GC-related data from The Cancer Genome Atlas and Gene Expression Omnibus databases, while R software (version 4.2.1) was used for correlation analysis.
Research results
Through the above analysis, we found that the didisulfidptosis-related gene may be related to the prognosis of GC. Six genes, namely, PLS3, GRP, APOD, SGCE, COL8A1, and VAMP7, constitute a predictive model for GC prognosis. APOD is a potential therapeutic target. Bosutinib and other drugs are suitable for the treatment of GC.
Research conclusions
The results of this study indicate that didisulfidptosis is related to the prognosis and treatment of GC. Additionally, APOD can be used as a potential therapeutic target for GC.
Research perspectives
Six genes, namely, PLS3, GRP, APOD, SGCE, COL8A1, and VAMP7, constitute a predictive model for GC prognosis. APOD is a potential therapeutic target for treating GC. Bosutinib and other drugs are suitable for the treatment of GC, although this requires further confirmation through molecular biology and clinical experiments.
